Transplantation of anergic histoincompatible bone marrow allografts.

Source:http://linkedlifedata.com/resource/pubmed/id/10352162

N. Engl. J. Med. 1999 Jun 3 340 22 1704-14

Download in:

View as

General Info

Authors

Hirano N, Nadler LM, Boussiotis VA, Neuberg D, Gribben JG, Guinan EC, Brennan LL

Affiliation

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. evavguinan@dfci.harvard.edu

Abstract

Successful allogeneic bone marrow transplantation relies on global immunosuppression or elimination of T cells. In contrast, the induction of anergy can inactivate specific sets of alloreactive T cells in the donor marrow. Previous work has shown that anergy can be induced by blocking the interaction of the B7 molecule on the surface of antigen-presenting cells with the CD28 molecule on the surface of T cells, thus preventing key signaling events essential for the activation of T cells. To investigate the feasibility of this approach with respect to transplantation of histoincompatible bone marrow, we undertook a clinical trial of ex vivo induction of anergy in T cells present in donor marrow to recipient alloantigens.

PMID
10352162

Publication types

Clinical Trial; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't